search
Back to results

Treg Cells for AGVHD in Non-myeloablative UCB Transplant

Primary Purpose

Hematologic Malignancies

Status
Withdrawn
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
T Regulatory cells
Fludarabine
Cyclophosphamide
Total Body Irradiation
Sponsored by
Masonic Cancer Center, University of Minnesota
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Hematologic Malignancies focused on measuring Acute Leukemias, Burkitt's Lymphoma, Natural Killer Cell Malignancies, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome, Large-Cell Lymphoma, Hodgkin Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone B-Cell Lymphoma, Follicular Lymphoma:, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia

Eligibility Criteria

18 Years - 69 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Must be ≥18, but < 70 years of age with no matched 5/6 or 6/6 sibling donor - patients ≥ 70 and ≤ 75 years of age may be eligible if they have a Co-Morbidity score ≤ 2 (Appendix II)
  • Three UCB units composing the graft will be selected according to the current University of Minnesota umbilical cord blood graft selection algorithm.
  • Each UCB unit must be matched at 4-6 HLA-A, B, DRB1 antigens with the recipient. This may include 0-2 antigen mismatches at the A or B or DRB1 loci. Each unit must be a 4-6 HLA-A, B, DRB1 antigen match to each other, not necessarily at the same loci they are matched to the recipient.
  • Disease Criteria

    • Acute Leukemias: Must be in remission by morphology (<5% blasts). Note cytogenetic relapse or persistent disease without morphologic relapse is acceptable. Also a small percentage of blasts that is equivocal between marrow regeneration versus early relapse are acceptable provided there are no associated cytogenetic markers consistent with relapse.
  • Acute Lymphoblastic Leukemia (ALL) in first complete remission (CR1) that is NOT considered favorable-risk as defined by the presence of at least one of the following:

    • Adverse cytogenetics such as t(9;22), t(1;19), t(4;11), other MLL rearrangements
    • White blood cell counts of greater than 30,000/mcL (B-ALL) or greater than 100,000/mcL (T-ALL) at diagnosis
    • Recipient age older than 30 years at diagnosis
    • Time to CR greater than 4 weeks
  • Acute Myelogenous Leukemia (AML) in first complete remission (CR1) that is NOT considered as favorable-risk. Favorable risk is defined as having one of the following:

    • t(8,21) without CKIT mutation
    • inv(16) without CKIT mutation or t(16;16)
    • Normal karyotype with mutated NPM1 and not FLT-IND
    • Normal karyotype with double mutated CEBPA
    • APL in first molecular remission at end of consolidation
  • Acute Leukemias in 2nd or subsequent CR
  • Biphenotypic/Undifferentiated in first or subsequent CR, adult T-cell leukemia/lymphoma in first or subsequent complete remission (CR)

    • Burkitt's Lymphoma in CR2 or subsequent complete remission (CR)
    • Natural Killer Cell Malignancies
    • Chronic Myelogenous Leukemia: all types except refractory blast crisis. Chronic phase patients must have failed or been intolerant to at least one tyrosine-kinase inhibitor
    • Myelodysplastic Syndrome: any subtype including refractory anemia (RA) if severe pancytopenia or complex cytogenetics. Blasts must be less than 5%. If 5% or more requires induction therapy pre-transplant to reduce blast count to ≤5%.
    • Large-Cell Lymphoma, Hodgkin Lymphoma and Multiple Myeloma with chemotherapy sensitive disease that has failed or patients who are ineligible for an autologous transplant.
    • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Marginal Zone B-Cell Lymphoma, Follicular Lymphoma, which have progressed within 12 months of achieving a partial or complete remission. Patients who had remissions lasting > 12 months, are eligible after at least two prior therapies. Patients with bulky disease should be considered for debulking chemotherapy before transplant. Patients with refractory disease are eligible, unless has bulky disease and an estimated tumor doubling time of less than one month.
    • Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia are eligible after initial therapy if chemotherapy sensitive.

Patients must have undergone an autologous transplant ≤ 12 months prior to allogeneic transplantation or have received multi-agent or immunosuppressive chemotherapy within 3 months of the preparative regimen.

  • Adequate performance status defined as a Karnofsky score ≥ 70%
  • Adequate organ function within 14 days (30 days for cardiac and pulmonary) of enrollment defined as:

    • Renal: creatinine < 2.0 mg/dL, for patient with a creatinine > 1.2 mg/dL or a history of renal dysfunction an estimated glomerular filtration rate > 40 mL/min/1.73 m2 is required
    • Hepatic: bilirubin, AST, ALT, alkaline phosphatase < 5 x upper limit of normal,
    • Pulmonary function: DLCOcorr > 40% normal,
    • Cardiac: left ventricular ejection fraction > 35%
  • Voluntary written consent signed before performance of any study-related procedure not part of normal medical care

Exclusion Criteria:

  • Untreated active infection at time of transplantation
  • History of HIV infection
  • Pregnant or breast feeding. The agents used in this study may be teratogenic to a fetus and there is no information on the excretion of agents into breast milk. Females of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy
  • Prior allogeneic transplantation
  • Less than 3 months from myeloablative conditioning for autologous transplantation

Sites / Locations

  • University of Minnesota Masonic Cancer Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

TREG

Non-Myeloablative Only

Arm Description

T regulatory cells after non-myeloablative (using fludarabine, cyclophosphamide, and total body irradiation) umbilical cord transplant.

Non-myeloablative (using fludarabine, cyclophosphamide, and total body irradiation) umbilical cord transplant.

Outcomes

Primary Outcome Measures

Incidence of grade II-IV acute graft-versus-host disease
Determine if 3:1 ratio of Treg:CD3+ cells reduces the risk grade II-IV acute graft versus host disease of 20% by day 100 as compared to patients with hematological malignancy receiving same conditioning regimen and immunosuppression but no Tregs.

Secondary Outcome Measures

Incidence of double and single unit chimerism
Compare the incidence of double and single unit chimerism at day +100 between Treg and controls
Incidence of grade III-IV acute graft-versus-host disease
Compare the incidence of grade III-IV aGVHD between Treg and controls
Incidence of viral and fungal infections
Compare the incidence of viral and fungal infections at 1 year between Treg and controls
Survival
Compare the probability of survival at 1 year between Treg and controls
Incidence of neutrophil recovery
Compare the incidence of neutrophil recovery at day 42 between Treg and controls
Incidence of treatment related mortality
Determine the incidence of treatment related mortality (TRM) at 6 months between Treg and controls
Incidence of platelet recovery
Compare the incidence of platelet recovery at 1 year between Treg and controls
Incidence of chronic GVHD
Compare the incidence of chronic GVHD at 1 year between Treg and controls
Incidence of relapse
Compare the incidence of relapse at 1 year between Treg and controls

Full Information

First Posted
March 26, 2014
Last Updated
November 29, 2017
Sponsor
Masonic Cancer Center, University of Minnesota
Collaborators
National Institutes of Health (NIH), National Cancer Institute (NCI)
search

1. Study Identification

Unique Protocol Identification Number
NCT02118311
Brief Title
Treg Cells for AGVHD in Non-myeloablative UCB Transplant
Official Title
T Regulatory Cell for Suppression of Acute Graft-vs-Host-Disease in Recipients of a Non-Myeloablative Umbilical Cord Blood Transplantation for Treatment of Hematological Malignancies
Study Type
Interventional

2. Study Status

Record Verification Date
November 2017
Overall Recruitment Status
Withdrawn
Why Stopped
Changing study design. Will replace with a different protocol.
Study Start Date
June 2016 (undefined)
Primary Completion Date
September 2018 (Anticipated)
Study Completion Date
September 2018 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Masonic Cancer Center, University of Minnesota
Collaborators
National Institutes of Health (NIH), National Cancer Institute (NCI)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a Simon's optimal two-stage phase II trial designed to estimate grade II-IV acute graft-versus-host disease (GVHD) after infusion of T regulatory (nTreg) in a fixed dose ratio to the combined CD3+ cell count of the two graft units in recipients of double UCB transplantation. The nTreg cells (manufactured from a 3rd cord blood unit) are infused on day 0 at least 1 hour after the 2nd unit of the double umbilical cord blood (UCB) transplant. The nTreg cells require an 18 day (±2 days) lead time based on the planned transplant day. The combined CD3+ cell content from the two graft UCB units is enumerated upon thaw (day 0). The patient then receives the number of nTregs cells from the 3rd cord product to achieve a Treg:CD3+ cells ratio of 5:1. The nTreg cell dose depends on the CD3+ cell content of the two graft UCB graft units, but it will not exceed the highest dose level safely tested in the ongoing University of Minnesota phase I Treg dose escalation study MT 2006-01.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hematologic Malignancies
Keywords
Acute Leukemias, Burkitt's Lymphoma, Natural Killer Cell Malignancies, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome, Large-Cell Lymphoma, Hodgkin Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone B-Cell Lymphoma, Follicular Lymphoma:, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
TREG
Arm Type
Experimental
Arm Description
T regulatory cells after non-myeloablative (using fludarabine, cyclophosphamide, and total body irradiation) umbilical cord transplant.
Arm Title
Non-Myeloablative Only
Arm Type
Experimental
Arm Description
Non-myeloablative (using fludarabine, cyclophosphamide, and total body irradiation) umbilical cord transplant.
Intervention Type
Biological
Intervention Name(s)
T Regulatory cells
Other Intervention Name(s)
nTreg, Treg
Intervention Description
Fixed dose of nTreg cells will be infused on day 0 of transplant after the umbilical cord blood cells
Intervention Type
Drug
Intervention Name(s)
Fludarabine
Other Intervention Name(s)
Fludara
Intervention Description
Fludarabine 30mg/m^2 IV over 1 hour on days -6 through -2 from transplant
Intervention Type
Drug
Intervention Name(s)
Cyclophosphamide
Other Intervention Name(s)
Endoxan, Cytoxan, Neosar, Procytox, Revimmune
Intervention Description
Cyclophosphamide 50 mg/kg IV over 2 hours on day -6 from transplant
Intervention Type
Radiation
Intervention Name(s)
Total Body Irradiation
Other Intervention Name(s)
TBI
Intervention Description
Total Body Irradiation (TBI) 200 cGy administered on day -1 in a single fraction will be given at a dose rate of 10-19 cGy/minute prescribed to the midplane of the patient at the level of the umbilicus.
Primary Outcome Measure Information:
Title
Incidence of grade II-IV acute graft-versus-host disease
Description
Determine if 3:1 ratio of Treg:CD3+ cells reduces the risk grade II-IV acute graft versus host disease of 20% by day 100 as compared to patients with hematological malignancy receiving same conditioning regimen and immunosuppression but no Tregs.
Time Frame
Day +100
Secondary Outcome Measure Information:
Title
Incidence of double and single unit chimerism
Description
Compare the incidence of double and single unit chimerism at day +100 between Treg and controls
Time Frame
Day +100
Title
Incidence of grade III-IV acute graft-versus-host disease
Description
Compare the incidence of grade III-IV aGVHD between Treg and controls
Time Frame
Day +100
Title
Incidence of viral and fungal infections
Description
Compare the incidence of viral and fungal infections at 1 year between Treg and controls
Time Frame
1 year
Title
Survival
Description
Compare the probability of survival at 1 year between Treg and controls
Time Frame
1 year
Title
Incidence of neutrophil recovery
Description
Compare the incidence of neutrophil recovery at day 42 between Treg and controls
Time Frame
Day 42
Title
Incidence of treatment related mortality
Description
Determine the incidence of treatment related mortality (TRM) at 6 months between Treg and controls
Time Frame
6 months
Title
Incidence of platelet recovery
Description
Compare the incidence of platelet recovery at 1 year between Treg and controls
Time Frame
1 year
Title
Incidence of chronic GVHD
Description
Compare the incidence of chronic GVHD at 1 year between Treg and controls
Time Frame
1 year
Title
Incidence of relapse
Description
Compare the incidence of relapse at 1 year between Treg and controls
Time Frame
1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
69 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Must be ≥18, but < 70 years of age with no matched 5/6 or 6/6 sibling donor - patients ≥ 70 and ≤ 75 years of age may be eligible if they have a Co-Morbidity score ≤ 2 (Appendix II) Three UCB units composing the graft will be selected according to the current University of Minnesota umbilical cord blood graft selection algorithm. Each UCB unit must be matched at 4-6 HLA-A, B, DRB1 antigens with the recipient. This may include 0-2 antigen mismatches at the A or B or DRB1 loci. Each unit must be a 4-6 HLA-A, B, DRB1 antigen match to each other, not necessarily at the same loci they are matched to the recipient. Disease Criteria Acute Leukemias: Must be in remission by morphology (<5% blasts). Note cytogenetic relapse or persistent disease without morphologic relapse is acceptable. Also a small percentage of blasts that is equivocal between marrow regeneration versus early relapse are acceptable provided there are no associated cytogenetic markers consistent with relapse. Acute Lymphoblastic Leukemia (ALL) in first complete remission (CR1) that is NOT considered favorable-risk as defined by the presence of at least one of the following: Adverse cytogenetics such as t(9;22), t(1;19), t(4;11), other MLL rearrangements White blood cell counts of greater than 30,000/mcL (B-ALL) or greater than 100,000/mcL (T-ALL) at diagnosis Recipient age older than 30 years at diagnosis Time to CR greater than 4 weeks Acute Myelogenous Leukemia (AML) in first complete remission (CR1) that is NOT considered as favorable-risk. Favorable risk is defined as having one of the following: t(8,21) without CKIT mutation inv(16) without CKIT mutation or t(16;16) Normal karyotype with mutated NPM1 and not FLT-IND Normal karyotype with double mutated CEBPA APL in first molecular remission at end of consolidation Acute Leukemias in 2nd or subsequent CR Biphenotypic/Undifferentiated in first or subsequent CR, adult T-cell leukemia/lymphoma in first or subsequent complete remission (CR) Burkitt's Lymphoma in CR2 or subsequent complete remission (CR) Natural Killer Cell Malignancies Chronic Myelogenous Leukemia: all types except refractory blast crisis. Chronic phase patients must have failed or been intolerant to at least one tyrosine-kinase inhibitor Myelodysplastic Syndrome: any subtype including refractory anemia (RA) if severe pancytopenia or complex cytogenetics. Blasts must be less than 5%. If 5% or more requires induction therapy pre-transplant to reduce blast count to ≤5%. Large-Cell Lymphoma, Hodgkin Lymphoma and Multiple Myeloma with chemotherapy sensitive disease that has failed or patients who are ineligible for an autologous transplant. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Marginal Zone B-Cell Lymphoma, Follicular Lymphoma, which have progressed within 12 months of achieving a partial or complete remission. Patients who had remissions lasting > 12 months, are eligible after at least two prior therapies. Patients with bulky disease should be considered for debulking chemotherapy before transplant. Patients with refractory disease are eligible, unless has bulky disease and an estimated tumor doubling time of less than one month. Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia are eligible after initial therapy if chemotherapy sensitive. Patients must have undergone an autologous transplant ≤ 12 months prior to allogeneic transplantation or have received multi-agent or immunosuppressive chemotherapy within 3 months of the preparative regimen. Adequate performance status defined as a Karnofsky score ≥ 70% Adequate organ function within 14 days (30 days for cardiac and pulmonary) of enrollment defined as: Renal: creatinine < 2.0 mg/dL, for patient with a creatinine > 1.2 mg/dL or a history of renal dysfunction an estimated glomerular filtration rate > 40 mL/min/1.73 m2 is required Hepatic: bilirubin, AST, ALT, alkaline phosphatase < 5 x upper limit of normal, Pulmonary function: DLCOcorr > 40% normal, Cardiac: left ventricular ejection fraction > 35% Voluntary written consent signed before performance of any study-related procedure not part of normal medical care Exclusion Criteria: Untreated active infection at time of transplantation History of HIV infection Pregnant or breast feeding. The agents used in this study may be teratogenic to a fetus and there is no information on the excretion of agents into breast milk. Females of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy Prior allogeneic transplantation Less than 3 months from myeloablative conditioning for autologous transplantation
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Claudio Brunstein, MD, PhD
Organizational Affiliation
University of Minnesota
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Minnesota Masonic Cancer Center
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55455
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Treg Cells for AGVHD in Non-myeloablative UCB Transplant

We'll reach out to this number within 24 hrs